Stockscreener 앱 받기
74.77
4.37%
-3.42
시간 외 거래:
74.53
-0.24
-0.32%
전일 마감가:
$78.19
열려 있는:
$78.82
하루 거래량:
4.99M
Relative Volume:
0.94
시가총액:
$28.85B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
31.98
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
+2.75%
1개월 성능:
+23.36%
6개월 성능:
+10.67%
1년 성능:
-11.85%
1일 변동 폭
$74.64
$78.91
1주일 범위
$71.53
$78.91
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
74.77 | 30.17B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
89.17 | 158.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.84 | 120.38B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.25 | 105.25B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.34 | 72.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.98 | 50.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
TD Cowen raises DexCom stock price target to $95 on data - Investing.com
TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating - marketscreener.com
DexCom Inc (DXCM)'s Winning Formula: Financial Metrics and Compe - GuruFocus
Is DexCom stock underperforming the Dow? - MSN
Dexcom stock (US2521311074): Mizuho lifts target after diabetes study - AD HOC NEWS
Pumps, patches and fixes at the ADA - BioWorld News
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom bolsters evidence for glucose sensors for Type 2 diabetes - MedTech Dive
Devon Energy Corp stock (US2521311074): Dividend, oil price moves and what matters for investors - AD HOC NEWS
Mizuho raises Dexcom stock price target to $85 on diabetes study - Investing.com
Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DexCom Inc (DXCM) Stock Up 5.2% and Still Undervalued -- GF Scor - GuruFocus
Dexcom reports positive CONNECT data for non-insulin diabetes - MSN
Clinical Wins Boost Dexcom Growth Story In Type 2 DiabetesDexCom (NASDAQ:DXCM) - Benzinga
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance Singapore
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes - Yahoo Finance Singapore
DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption - Quiver Quantitative
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating - marketscreener.com
Here's why you should retain DexCom stock in your portfolio - MSN
DexCom, Inc. (DXCM): Investor Outlook Reveals 13.92% Potential Upside In Continuous Glucose Monitoring Market - DirectorsTalk Interviews
DexCom (DXCM) Reports Positive Trial Results for Glucose Control in Type 2 Diabetes - GuruFocus
Is It Time To Reassess DexCom (DXCM) After Recent Glucose Monitoring Headlines? - Sahm
Dexcom G7 gave Type 2 adults 5 extra hours a day in range - Stock Titan
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin - The AI Journal
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study - Reuters
DexCom, Inc. Announces Results From CONNECT Randomized Controlled Trial Demonstrating Use Of Dexcom G7 Leads To Clinically And Statistically Significant Reduction In A1C And Improvement In Glucose Control Among People With Type 2 Diabetes N - marketscreener.com
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum - Yahoo Finance
Dexcom (DXCM) EVP Jon Coleman sells 9,823 shares in planned trades - Stock Titan
Dexcom buys Nutrisense; Insulet rolls out patch pump update - MedTech Dive
Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating - marketscreener.com
Is DexCom Stock Underperforming the Dow? - Yahoo Finance
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DXCM (NASDAQ: DXCM) affiliate files Form 144; director sold 4,912 shares - Stock Titan
Here's Why You Should Retain DexCom Stock in Your Portfolio - The Globe and Mail
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Showcases Innovations and Future Plans at ADA Scie - GuruFocus
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 - StreetInsider
DexCom vs. Insulet: Growth Trajectories and Valuations for InvestorsNews and Statistics - IndexBox
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? - Yahoo Finance
Dexcom Reaffirms CGM Benefits for All People With Diabetes and C - GuruFocus
Dexcom to present diabetes study, launch new app, acquire Nutrisense By Investing.com - Investing.com Nigeria
Dexcom to present diabetes study, launch new app, acquire Nutrisense - Investing.com
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 – Company AnnouncementFT.com - Financial Times
Elliott strikes Dexcom board settlement after taking stake - MSN
[144] DEXCOM INC SEC Filing - Stock Titan
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative? - Yahoo Finance
Dexcom Inc. stock (US2521311074): customer advisory report and recent trading in focus - AD HOC NEWS
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
The FDA Has Issued a Warning on 2 Popular Glucose Monitors. You Won't Believe Why. - Men's Health
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Coleman Jon | EVP, Chief Commercial Officer |
Jun 03 '26 |
Sale |
73.00 |
4,912 |
358,576 |
100,361 |
3.41%
자본화:
|
볼륨(24시간):